Amalgamated Bank Sells 1,082 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Amalgamated Bank cut its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 5.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 19,872 shares of the life sciences company’s stock after selling 1,082 shares during the quarter. Amalgamated Bank’s holdings in Integra LifeSciences were worth $361,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of IART. Blue Trust Inc. increased its stake in Integra LifeSciences by 100.5% during the 2nd quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 444 shares in the last quarter. CWM LLC grew its holdings in shares of Integra LifeSciences by 50.8% during the second quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock valued at $37,000 after buying an additional 425 shares during the last quarter. Northwest Investment Counselors LLC bought a new stake in shares of Integra LifeSciences during the third quarter valued at approximately $73,000. Canada Pension Plan Investment Board purchased a new position in Integra LifeSciences in the 2nd quarter worth approximately $114,000. Finally, Allspring Global Investments Holdings LLC lifted its position in Integra LifeSciences by 58.0% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 4,662 shares of the life sciences company’s stock valued at $136,000 after acquiring an additional 1,711 shares in the last quarter. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on IART. Bank of America reduced their target price on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a report on Monday, October 7th. Citigroup lifted their price objective on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a report on Tuesday, November 5th. Truist Financial dropped their price target on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a report on Monday, October 14th. JMP Securities decreased their price objective on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a report on Tuesday, July 30th. Finally, BTIG Research upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a report on Monday, October 7th. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, Integra LifeSciences currently has an average rating of “Hold” and a consensus target price of $24.00.

Integra LifeSciences Price Performance

Shares of NASDAQ:IART opened at $22.88 on Monday. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The stock has a market capitalization of $1.77 billion, a PE ratio of -254.19, a price-to-earnings-growth ratio of 0.78 and a beta of 1.08. The firm’s 50 day moving average price is $19.54 and its 200-day moving average price is $24.14. Integra LifeSciences Holdings Co. has a twelve month low of $16.81 and a twelve month high of $45.42.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.02. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The business had revenue of $380.80 million for the quarter, compared to the consensus estimate of $375.81 million. During the same period last year, the firm earned $0.76 earnings per share. The company’s quarterly revenue was down .4% on a year-over-year basis. Equities research analysts expect that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.